Full Text View
Tabular View
No Study Results Posted
Related Studies
Double Blinded Randomized Comparison Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test
This study has been completed.
First Received: April 15, 2009   Last Updated: April 16, 2009   History of Changes
Sponsored by: Baystate Medical Center
Information provided by: Baystate Medical Center
ClinicalTrials.gov Identifier: NCT00883103
  Purpose

When compared to aqueous gel, 2% Lidocaine jelly does not reduce the pain perception during evaluation of postvoid residual volume and the Q-tip test.


Condition Intervention Phase
Pain
Drug: 2% Lidocaine jelly
Drug: Plain aqueous gel
Phase IV

Drug Information available for: Lidocaine
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Double Blinded Randomized Comparison Between Lidocaine Jelly And Plain Aqueous Gel For Urethral Straight Catheterization And The Q-Tip Test

Further study details as provided by Baystate Medical Center:

Primary Outcome Measures:
  • patient's perception of pain level measured with a validated pain scoring system, the Wong-Baker FACES visual scale where 0 represented no pain and 5 represented worst imaginable pain [ Designated as safety issue: No ]

Enrollment: 137
Study Start Date: November 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Drug: 2% Lidocaine jelly
2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
2: Placebo Comparator
Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
Drug: Plain aqueous gel
Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.

Detailed Description:

This study was approved by the institutional review board at Baystate Medical Center. The study pool consists of all women who present to a single urogynecologist's office for an initial consultation with a complaint of urinary incontinence and/or pelvic organ prolapse. Those patients who consent for the research will be then randomized either to 2% Lidocaine Hydrochloride jelly (Akorn, Buffalo Grove, IL) or Surgilube (Fougera, Melville, NY) using computer generated blocks of 10. The latter is a commonly used, commercially available aqueous lubricant gel. Both the urogynecologist who perform the examinations and the patient will be blinded to the randomization. The appearances of the study gels are indistinguishable. Based on our power analysis targeting a power of 0.80, an α value of 0.05, and 20% difference in pain perception between the groups, we are aiming to recruit a sample of minimum132 subjects. First, demographic information including the age, parity, previous vaginal births, body mass index, race, diabetes, vaginal atrophy, neurological impairment, current estrogen use, indication for visit and exam anxiety will be collected as a part of patient history. Immediately after voiding, each patient will be placed in a lithotomy position. An independent nurse who is not involved in patient's care will prepare the study gels according to the randomization. After cleansing external urethral meatus with povidone iodine solution, a lubricated a sterile 14-French polyvinyl chloride Mentor Self-Cath catheter (Coloplast, Minneapolis, MN) will be placed transurethrally into the bladder to measure the postvoid residual volume. Following removal of the catheter, a cotton swab, lubricated with the same allocated gel, will be advanced to the urethrovesical junction until resistance was felt. The angle of the Q-tip with the horizontal plane will be measured at rest and with Valsalva maneuver. All the examinations will be performed by the same urogynecologist in the same order. Immediately following the Q-tip test, patient's perception of pain level will be measured using a validated pain scoring system, the Wong-Baker FACES visual scale where 0 represented no pain and 5 represented worst imaginable pain. The rest of the physical examination will be completed after this pain assessment. We will evaluate patient characteristics and pain score variables by exposure to either Lidocaine or Surgilube using SPSS Version 11.01 software (Chicago, Illinois). For continuous variables, we will calculate the mean and standard deviation and then evaluate significant differences using the Mann Whitney U test. For categorical variables, we will calculate the number and percent and then evaluate significant differences using Pearson's chi-square test. Significance for all results was set at an alpha of <0.05.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All women who presented to a single urogynecologist's office for an initial consultation with a complaint of urinary incontinence and/or pelvic organ prolapse

Exclusion Criteria:

  • Being a minor
  • Pregnancy
  • Allergy to Lidocaine or aqueous lubricant gel
  • Any current use of analgesia
  • Structural abnormalities of the urethra
  • Active genital Herpes or other vulvovaginal infections or inability to cooperate with pain assessment due to mental disorders.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00883103

Locations
United States, Massachusetts
Baystate Medical Center
Springfield, Massachusetts, United States, 01199
Sponsors and Collaborators
Baystate Medical Center
Investigators
Principal Investigator: Oz Harmanli, MD Baystate Medical Center
  More Information

No publications provided

Responsible Party: Baystate Medical Center ( Oz Harmanli, MD )
Study ID Numbers: 07-091
Study First Received: April 15, 2009
Last Updated: April 16, 2009
ClinicalTrials.gov Identifier: NCT00883103     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Baystate Medical Center:
female urethral catheterization
Lidocaine
lubricant
Q-tip test
Q tip test
K-Y jelly
pain perception for urethral straight catheterization and the Q-tip test

Study placed in the following topic categories:
Lidocaine
Central Nervous System Depressants
Anesthetics
Pain
Cardiovascular Agents
Anti-Arrhythmia Agents
Peripheral Nervous System Agents
Anesthetics, Local

Additional relevant MeSH terms:
Sensory System Agents
Therapeutic Uses
Physiological Effects of Drugs
Lidocaine
Central Nervous System Depressants
Anesthetics
Cardiovascular Agents
Anti-Arrhythmia Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions
Anesthetics, Local

ClinicalTrials.gov processed this record on May 06, 2009